dipyridamole has been researched along with Pneumonia in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Counterproductive lung inflammation and dysregulated thrombosis contribute importantly to the lethality of advanced COVID-19." | 1.56 | Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. ( Barroso-Aranda, J; DiNicolantonio, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| DiNicolantonio, JJ | 1 |
| Barroso-Aranda, J | 1 |
| Shurygin, DIa | 1 |
| Chireĭkin, LV | 1 |
| Mednikov, BL | 1 |
2 other studies available for dipyridamole and Pneumonia
| Article | Year |
|---|---|
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
Topics: Adenosine A2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; C | 2020 |
[Characteristics of the hemostatic system in acute pneumonias at an early age].
Topics: Acute Disease; Adult; Dipyridamole; Drug Evaluation; Factor XIII; Fibrin Fibrinogen Degradation Prod | 1980 |